The DOI matches its Crossref record.
Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs?
Abstract
Despite numerous attempts over 16 years, the results of aldose reductase inhibitor (ARI) trials for the treatment of diabetic neuropathy have not proven efficacy. This paper reviews each of the ARI trials, examines confounding factors, and proposes a future course. The confounding factors considered are pharmacokinetics (ARI penetration of human nerve), length of trial (in terms of the natural history of diabetic neuropathy), trial endpoints (reversibility or slowing of progression), reproducibility of clinical measurements (in terms of power calculations), standardization and quality control of endpoints, and clinically meaningful differences in endpoints. We conclude that ARIs are most likely to have a beneficial effect in the management of diabetic distal symmetrical polyneuropathy and autonomic neuropathy but that the clinical role of ARIs is to slow the progression of diabetic neuropathy rather than to reverse it. Future trials should be designed with adequate statistical power, with consideration of the variability of the endpoint measurements for long enough duration, and with rigorous quality control to definitively confirm the utility of ARIs in the treatment of diabetic distal symmetrical polyneuropathy and autonomic neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vinik, A. I., Maser, R. E., Mitchell, B. D., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1553 · Cited by 2,044
Backonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533
Endothelial dysfunction in diabetes
De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., Lameire, N. H., & Vanhoutte, P. M. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703393 · Cited by 1,165
The spectrum of neuropathy in diabetes and impaired glucose tolerance
Sumner, C. J., Sheth, S., Griffin, J. W., Cornblath, D. R., & Polydefkis, M. (2003) · Neurology · doi:10.1212/wnl.60.1.108 · Cited by 708
Tomlinson, D. R., & Gardiner, N. J. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2294 · Cited by 564
The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification
Barski, O. A., Tipparaju, S. M., & Bhatnagar, A. (2008) · Drug Metabolism Reviews · doi:10.1080/03602530802431439 · Cited by 542
Srivastava, S. K., Ramana, K. V., & Bhatnagar, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0028 · Cited by 527
Yabe-Nishimura, C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01347-4 · Cited by 526
Mechanism of diabetic neuropathy: Where are we now and where to go?
Yagihashi, S., Mizukami, H., & Sugimoto, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00070.x · Cited by 488
Polydefkis, M., Hauer, P., Sheth, S., Sirdofsky, M., Griffin, J. W., & McArthur, J. C. (2004) · Brain · doi:10.1093/brain/awh175 · Cited by 375
Polyol pathway and diabetic peripheral neuropathy
Oates, P. J. (2002) · International Review of Neurobiology · doi:10.1016/s0074-7742(02)50082-9 · Cited by 322
Protein kinase C and the development of diabetic vascular complications
Way, K. J., Katai, N., & King, G. L. (2001) · Diabetic Medicine · doi:10.1046/j.0742-3071.2001.00638.x · Cited by 313
Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones
Bruno, G., Costantino, L., Curinga, C., Maccari, R., Monforte, F., Nicolò, F., Ottanà, R., & Vigorita, M. G. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00366-2 · Cited by 252
Metadata
- Authors
- Pfeifer, M. A., Schumer, M. P., & Gelber, D. A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1997-09-01
- Volume
- 46
- Issue
- Supplement_2
- Pages
- S82-S89
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2134045814
- Cited by
- 194
- References
- 0
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.